ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

HCT and WBC Control in Polycythemia Vera

Mary Frances McMullin

ASH 2024 Insights: Final Analysis of Pegylated Interferon in PV and …

2024 ASH Annual Meeting Insights Hub

L. Masarova

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

A Decade of Ruxolitinib in Polycythemia Vera: Clinical Efficacy and …

Lucia Masarova